Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria
Non-interventional, Multicenter, Prospective Register Study to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (ROC) Patients in Austria
1 other identifier
observational
150
1 country
9
Brief Summary
Various treatment options exist for patients with platinum-sensitive relapsed epithelial ovarian cancer (ROC). The register will provide an overview of chosen treatments including the reasons, why these options were chosen.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2018
Longer than P75 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 9, 2018
CompletedFirst Submitted
Initial submission to the registry
April 27, 2020
CompletedFirst Posted
Study publicly available on registry
April 30, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2025
CompletedMarch 28, 2023
March 1, 2023
6.3 years
April 27, 2020
March 27, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
To assess treatment patterns and the reasons for selecting these treatments in patients with platinum-sensitive ROC after first relapse in Austria
Descriptive Data Analysis
Two years
Secondary Outcomes (4)
Progression Free Survival
2 years per patient
Overall Survival
2 years per patient
Assess Treatments
2 years per patient
Overall Survival Description
2 years per patient
Eligibility Criteria
Patients at their first platinum-sensitive ROC treated within gynecological oncology centers in Austria participating in the register.
You may qualify if:
- Women aged 18 years or older
- Presence of first platinum-sensitive ROC (ovarian, peritoneal and/or fallopian tube cancer)
- Must have received at least 4 cycles of chemotherapy during primary therapy
- Patients must not have more than 1 prior line of chemotherapy
- Signed informed consent
You may not qualify if:
- No knowledge of spoken and written German
- Signed informed consent is not given
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
Medical University Graz
Graz, Austria
Medical University Innsbruck
Innsbruck, Austria
Bezirkskrankenhaus Kufstein
Kufstein, Austria
LKH Hochsteiermark
Leoben, Austria
Bezirkskrankenhaus Lienz
Lienz, Austria
Kepler Universitätsklinikum Linz
Linz, Austria
Ordensklinikum Linz
Linz, Austria
Krankenhaus der Barmherzigen Schwestern Ried
Ried im Innkreis, Austria
Medical University Vienna
Vienna, Austria
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lukas Hefler, Prim. Dr.
Ordensklinikum Linz
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 27, 2020
First Posted
April 30, 2020
Study Start
August 9, 2018
Primary Completion
December 1, 2024
Study Completion
August 1, 2025
Last Updated
March 28, 2023
Record last verified: 2023-03